Pub Date : 2024-01-13DOI: 10.61427/jcpr.v4.i1.2024.119
V. Jyothi Krishna, L. Swathi, S. S. Lakshmi
This review article investigates recent advancements in drug delivery systems, with a specific emphasis on integrating nanotechnology and immunotherapy for precision cancer therapy. This review explores the design, development, and optimization of novel drug delivery platforms aimed at improving drug efficacy, minimizing side effects and enhancing patient outcomes. The synergistic interplay between nanocarriers and immunotherapeutic agents shows significant potential in addressing current challenges in cancer treatment, such as drug resistance and off-target effects. This article reviews recent preclinical and clinical studies, highlighting the transformative potential of these innovative approaches to reshape cancer therapeutics and facilitate the advent of personalized medicine in oncology. The research findings contribute to the ongoing initiatives aimed at refining the effectiveness and safety of pharmaceutical interventions, bringing us one step closer to more efficient and targeted cancer treatments.
{"title":"Integrating Immunotherapy and Nanotechnology in Advanced Drug Delivery Systems for Precision Cancer Therapy","authors":"V. Jyothi Krishna, L. Swathi, S. S. Lakshmi","doi":"10.61427/jcpr.v4.i1.2024.119","DOIUrl":"https://doi.org/10.61427/jcpr.v4.i1.2024.119","url":null,"abstract":"This review article investigates recent advancements in drug delivery systems, with a specific emphasis on integrating nanotechnology and immunotherapy for precision cancer therapy. This review explores the design, development, and optimization of novel drug delivery platforms aimed at improving drug efficacy, minimizing side effects and enhancing patient outcomes. The synergistic interplay between nanocarriers and immunotherapeutic agents shows significant potential in addressing current challenges in cancer treatment, such as drug resistance and off-target effects. This article reviews recent preclinical and clinical studies, highlighting the transformative potential of these innovative approaches to reshape cancer therapeutics and facilitate the advent of personalized medicine in oncology. The research findings contribute to the ongoing initiatives aimed at refining the effectiveness and safety of pharmaceutical interventions, bringing us one step closer to more efficient and targeted cancer treatments.","PeriodicalId":513179,"journal":{"name":"Journal of Clinical and Pharmaceutical Research","volume":"8 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140509150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-13DOI: 10.61427/jcpr.v4.i1.2024.118
V. Jyothi Krishna, Ch. Kesari
This article provides a thorough examination of recent progress in gene therapy as a transformative avenue for treating rare diseases characterized by genetic mutations. The authors explore fundamental principles of gene therapy, encompassing both viral and non-viral vectors employed for efficient gene delivery. This article delves into the potential of state-of-the-art genome-editing technologies, such as CRISPR/Cas9, to rectify genetic abnormalities, emphasizing their precision and scalability. Regulatory considerations and ethical implications surrounding gene therapy are discussed, underlining the importance of a balanced and responsible approach in translating these innovations into clinical practice. As gene therapy continues to evolve, its expanding role in addressing rare diseases offers hope to individuals grappling with these complex conditions.
{"title":"Impact of Gene Therapy and Genetic Mutations in Rare Diseases","authors":"V. Jyothi Krishna, Ch. Kesari","doi":"10.61427/jcpr.v4.i1.2024.118","DOIUrl":"https://doi.org/10.61427/jcpr.v4.i1.2024.118","url":null,"abstract":"This article provides a thorough examination of recent progress in gene therapy as a transformative avenue for treating rare diseases characterized by genetic mutations. The authors explore fundamental principles of gene therapy, encompassing both viral and non-viral vectors employed for efficient gene delivery. This article delves into the potential of state-of-the-art genome-editing technologies, such as CRISPR/Cas9, to rectify genetic abnormalities, emphasizing their precision and scalability. Regulatory considerations and ethical implications surrounding gene therapy are discussed, underlining the importance of a balanced and responsible approach in translating these innovations into clinical practice. As gene therapy continues to evolve, its expanding role in addressing rare diseases offers hope to individuals grappling with these complex conditions.","PeriodicalId":513179,"journal":{"name":"Journal of Clinical and Pharmaceutical Research","volume":"33 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140508755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-13DOI: 10.61427/jcpr.v4.i1.2024.115
Mukesh Kumar Saphi, Yalla Sai Vijaya Durga, Sunny Kumar Yadav, Krishnadev Shah, Amit Kumar
Plummer-Vinson syndrome, also called Paterson-Kelly syndrome, is characterized by the classic triad of dysphagia, iron-deficiency anemia, and esophageal webs. This syndrome is associated with an increased incidence of post-cricoid carcinoma and for surveillance, an endoscopy is recommended under general anesthesia. This was a case of 74-year-old woman with Plummer-Vinson Syndrome who was successfully treated with Savary-Gilliard (SG) dilation or Esophageal dilation. The patient had a long-standing clinical history of iron deficiency anemia with slow progression of dysphagia of solid food from 10 years and glossoepiglotic fold, aryepiglottic fold bilaterally arytenoid on the left & right side and had experienced difficulty in swallowing for the past 10 years. Along with this patient is having abdominal pain radiating to the epigastrium region and fever with chills & rigors. An endoscopy examination was conducted under general anesthesia and revealed the esophageal web at the level of the cervical esophagus. Laboratory data investigation shows an RBC count of 2.09 million/cumm, haemoglobin of 6.6 gm/dl%, and serum iron of 7µg/dl. The patient was prescribed Inj. Orofer-XT 100 mg intravenous iron sucrose supplement daily for 15 days, Inj. Pantoprazole 40 mg daily for 1 week, Inj. Tramadol 1amp whenever required and Syp.Sucralfate 15 ml 30 minutes before food. Her anemia condition was improved but dysphagia did not improve. To treat dysphagia the Savary-Gilliard (SG) dilation was done under fluoroscopy by endoscopically a single session was performed that serially increased the diameter by disrupting the web without any complication. After SG-dilation, the patient's dysphagia resolved shortly after the treatment.
{"title":"Plummer-Vinson Syndrome: A Rare Case Report","authors":"Mukesh Kumar Saphi, Yalla Sai Vijaya Durga, Sunny Kumar Yadav, Krishnadev Shah, Amit Kumar","doi":"10.61427/jcpr.v4.i1.2024.115","DOIUrl":"https://doi.org/10.61427/jcpr.v4.i1.2024.115","url":null,"abstract":"Plummer-Vinson syndrome, also called Paterson-Kelly syndrome, is characterized by the classic triad of dysphagia, iron-deficiency anemia, and esophageal webs. This syndrome is associated with an increased incidence of post-cricoid carcinoma and for surveillance, an endoscopy is recommended under general anesthesia. This was a case of 74-year-old woman with Plummer-Vinson Syndrome who was successfully treated with Savary-Gilliard (SG) dilation or Esophageal dilation. The patient had a long-standing clinical history of iron deficiency anemia with slow progression of dysphagia of solid food from 10 years and glossoepiglotic fold, aryepiglottic fold bilaterally arytenoid on the left & right side and had experienced difficulty in swallowing for the past 10 years. Along with this patient is having abdominal pain radiating to the epigastrium region and fever with chills & rigors. An endoscopy examination was conducted under general anesthesia and revealed the esophageal web at the level of the cervical esophagus. Laboratory data investigation shows an RBC count of 2.09 million/cumm, haemoglobin of 6.6 gm/dl%, and serum iron of 7µg/dl. The patient was prescribed Inj. Orofer-XT 100 mg intravenous iron sucrose supplement daily for 15 days, Inj. Pantoprazole 40 mg daily for 1 week, Inj. Tramadol 1amp whenever required and Syp.Sucralfate 15 ml 30 minutes before food. Her anemia condition was improved but dysphagia did not improve. To treat dysphagia the Savary-Gilliard (SG) dilation was done under fluoroscopy by endoscopically a single session was performed that serially increased the diameter by disrupting the web without any complication. After SG-dilation, the patient's dysphagia resolved shortly after the treatment.","PeriodicalId":513179,"journal":{"name":"Journal of Clinical and Pharmaceutical Research","volume":"20 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139531406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-13DOI: 10.61427/jcpr.v4.i1.2024.120
Slesha Kumar Kosuru, V. S. Rao, K.V.S.S. Annapurna, Bhagya Naga, Lakshmi Siripalli, D.Sri, Sai Sukruta, B. Tharuna, Mr. Slesha, Kumar Kosuru, M.Pharm
In recent years, the field of drug delivery has undergone a transformative shift with the introduction of innovative platforms that transcend conventional methods, providing accurate and efficient means for delivering therapeutic agents. This exploration delves into the distinctive features and potential impacts of these pioneering platforms, charting a course for the future of pharmaceutical interventions. In this review article, the advancements regarding the nanotechnology-enabled delivery, lipid-based drug delivery systems, targeted drug delivery, implantable drug delivery systems, 3D printing in drug delivery, stimuli-responsive delivery systems, mRNA and gene delivery platforms and microfluidic - based delivery systems were discussed. These innovative drug delivery platforms represent a dynamic frontier in pharmaceutical research and development. They afford unprecedented control over drug properties, release kinetics and targeting strategies. As research continues to push the boundaries of drug delivery science, these innovations hold the potential to revolutionize the treatment of various diseases, ushering in safer, more effective and patient-centric therapeutic solutions.
{"title":"A Review on Innovative Drug Delivery Platforms","authors":"Slesha Kumar Kosuru, V. S. Rao, K.V.S.S. Annapurna, Bhagya Naga, Lakshmi Siripalli, D.Sri, Sai Sukruta, B. Tharuna, Mr. Slesha, Kumar Kosuru, M.Pharm","doi":"10.61427/jcpr.v4.i1.2024.120","DOIUrl":"https://doi.org/10.61427/jcpr.v4.i1.2024.120","url":null,"abstract":"In recent years, the field of drug delivery has undergone a transformative shift with the introduction of innovative platforms that transcend conventional methods, providing accurate and efficient means for delivering therapeutic agents. This exploration delves into the distinctive features and potential impacts of these pioneering platforms, charting a course for the future of pharmaceutical interventions. In this review article, the advancements regarding the nanotechnology-enabled delivery, lipid-based drug delivery systems, targeted drug delivery, implantable drug delivery systems, 3D printing in drug delivery, stimuli-responsive delivery systems, mRNA and gene delivery platforms and microfluidic - based delivery systems were discussed. These innovative drug delivery platforms represent a dynamic frontier in pharmaceutical research and development. They afford unprecedented control over drug properties, release kinetics and targeting strategies. As research continues to push the boundaries of drug delivery science, these innovations hold the potential to revolutionize the treatment of various diseases, ushering in safer, more effective and patient-centric therapeutic solutions.","PeriodicalId":513179,"journal":{"name":"Journal of Clinical and Pharmaceutical Research","volume":"27 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140509067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-13DOI: 10.61427/jcpr.v4.i1.2024.121
Slesha Kumar Kosuru, Santhosh Gandham, Bhagya Naga Lakshmi Siripalli, K.V.S.S. Annapurna, D. Vinoothna, D. Vaishnavi
Embarking on precision pharmacogenomics journey is a transformative experience in the world of medicine. This innovative approach, distinct from traditional practices tailors treatments to each individual's unique genes. Unlike standard methods where everyone gets the same medicine, precision pharmacogenomics uses a person's genetic information as an approach to determine the most effective treatment. In this personalized medical adventure, the individual's genes act like a guide for healthcare providers. Moreover, there is a growing focus on ensuring equitable access to personalized medicine. Efforts to address healthcare disparities and promote inclusivity in genomic research are expected to take center stage. Ethical considerations and robust regulatory frameworks will play pivotal roles in guiding the responsible and transparent application of precision pharmacogenomics. The future of precision pharmacogenomics promises a healthcare landscape where treatments are finely tuned to the unique genetic makeup of each individual. This forward-looking perspective suggests a future characterized by enhanced effectiveness, reduced side effects and a more inclusive approach to personalized healthcare.
{"title":"Precision Pharmacogenomics: A Review","authors":"Slesha Kumar Kosuru, Santhosh Gandham, Bhagya Naga Lakshmi Siripalli, K.V.S.S. Annapurna, D. Vinoothna, D. Vaishnavi","doi":"10.61427/jcpr.v4.i1.2024.121","DOIUrl":"https://doi.org/10.61427/jcpr.v4.i1.2024.121","url":null,"abstract":"Embarking on precision pharmacogenomics journey is a transformative experience in the world of medicine. This innovative approach, distinct from traditional practices tailors treatments to each individual's unique genes. Unlike standard methods where everyone gets the same medicine, precision pharmacogenomics uses a person's genetic information as an approach to determine the most effective treatment. In this personalized medical adventure, the individual's genes act like a guide for healthcare providers. Moreover, there is a growing focus on ensuring equitable access to personalized medicine. Efforts to address healthcare disparities and promote inclusivity in genomic research are expected to take center stage. Ethical considerations and robust regulatory frameworks will play pivotal roles in guiding the responsible and transparent application of precision pharmacogenomics. The future of precision pharmacogenomics promises a healthcare landscape where treatments are finely tuned to the unique genetic makeup of each individual. This forward-looking perspective suggests a future characterized by enhanced effectiveness, reduced side effects and a more inclusive approach to personalized healthcare.","PeriodicalId":513179,"journal":{"name":"Journal of Clinical and Pharmaceutical Research","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140509088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In the pharmaceutical research and development, bioequivalence studies hold a critical position, serving as a vital component in evaluating the equivalence of generic drugs with their reference counterparts. These studies, which examine the interchangeability between generic and brand-name medications, depend heavily on a range of analytical techniques to measure the presence and concentration of a drug's active pharmaceutical ingredient (API) within the human body. The comprehensive use of these analytical methods ensures the confidence of healthcare providers and regulatory bodies in the effectiveness, quality and safety of generic medications. The field of pharmaceutical analysis is dynamic and forward-looking, with analysts, researchers and scientists energetically engaged in forging a future characterized by ground breaking discoveries and refined pharmaceutical solutions. This is a realm where scientific excellence and innovation harmonize, ultimately benefiting the health and welfare of individuals and societies across the globe. The key takeaways underscore the field's resilience and its unwavering commitment to upholding the highest standards in drug development and quality control while pioneering cutting-edge technologies with the promise of safer, more effective pharmaceuticals for all.
{"title":"A Brief Review on Analytical Techniques in Bioequivalence Studies","authors":"Slesha Kumar Kosuru, Tadi Suvarna Kosuru, Gunapati Jyothi, Kandregula Sai Siva Saran, Polinati Syam Sundhar","doi":"10.61427/jcpr.v4.i1.2024.117","DOIUrl":"https://doi.org/10.61427/jcpr.v4.i1.2024.117","url":null,"abstract":"In the pharmaceutical research and development, bioequivalence studies hold a critical position, serving as a vital component in evaluating the equivalence of generic drugs with their reference counterparts. These studies, which examine the interchangeability between generic and brand-name medications, depend heavily on a range of analytical techniques to measure the presence and concentration of a drug's active pharmaceutical ingredient (API) within the human body. The comprehensive use of these analytical methods ensures the confidence of healthcare providers and regulatory bodies in the effectiveness, quality and safety of generic medications. The field of pharmaceutical analysis is dynamic and forward-looking, with analysts, researchers and scientists energetically engaged in forging a future characterized by ground breaking discoveries and refined pharmaceutical solutions. This is a realm where scientific excellence and innovation harmonize, ultimately benefiting the health and welfare of individuals and societies across the globe. The key takeaways underscore the field's resilience and its unwavering commitment to upholding the highest standards in drug development and quality control while pioneering cutting-edge technologies with the promise of safer, more effective pharmaceuticals for all.","PeriodicalId":513179,"journal":{"name":"Journal of Clinical and Pharmaceutical Research","volume":"15 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140509351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：